These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 35140265)

  • 1. Aloin isoforms (A and B) selectively inhibits proteolytic and deubiquitinating activity of papain like protease (PLpro) of SARS-CoV-2 in vitro.
    Lewis DSM; Ho J; Wills S; Kawall A; Sharma A; Chavada K; Ebert MCCJC; Evoli S; Singh A; Rayalam S; Mody V; Taval S
    Sci Rep; 2022 Feb; 12(1):2145. PubMed ID: 35140265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization and noncovalent inhibition of the K63-deubiquitinase activity of SARS-cov-2 PLpro.
    Liu X; Zheng M; Zhang H; Feng B; Li J; Zhang Y; Zhang J; Zhao N; Li C; Song N; Song B; Yang D; Chen J; Qi A; Zhao L; Luo C; Zang Y; Liu H; Li J; Zhang B; Zhou Y; Zheng J
    Antiviral Res; 2024 Aug; 228():105944. PubMed ID: 38914283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ciclesonide Inhibits SARS-CoV-2 Papain-Like Protease in Vitro.
    Kiba Y; Tanikawa T; Kitamura M
    Biol Pharm Bull; 2024; 47(5):965-966. PubMed ID: 38763750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disrupting protease and deubiquitinase activities of SARS-CoV-2 papain-like protease by natural and synthetic products discovered through multiple computational and biochemical approaches.
    Waqas M; Ullah S; Ullah A; Halim SA; Rehman NU; Khalid A; Ali A; Khan A; Gibbons S; Csuk R; Al-Harrasi A
    Int J Biol Macromol; 2024 Oct; 277(Pt 4):134476. PubMed ID: 39111477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity.
    Shin D; Mukherjee R; Grewe D; Bojkova D; Baek K; Bhattacharya A; Schulz L; Widera M; Mehdipour AR; Tascher G; Geurink PP; Wilhelm A; van der Heden van Noort GJ; Ovaa H; Müller S; Knobeloch KP; Rajalingam K; Schulman BA; Cinatl J; Hummer G; Ciesek S; Dikic I
    Nature; 2020 Nov; 587(7835):657-662. PubMed ID: 32726803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unraveling antiviral efficacy of multifunctional immunomodulatory triterpenoids against SARS-COV-2 targeting main protease and papain-like protease.
    Choudhary S; Nehul S; Singh A; Panda PK; Kumar P; Sharma GK; Tomar S
    IUBMB Life; 2024 May; 76(5):228-241. PubMed ID: 38059400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2 proteases PLpro and 3CLpro cleave IRF3 and critical modulators of inflammatory pathways (NLRP12 and TAB1): implications for disease presentation across species.
    Moustaqil M; Ollivier E; Chiu HP; Van Tol S; Rudolffi-Soto P; Stevens C; Bhumkar A; Hunter DJB; Freiberg AN; Jacques D; Lee B; Sierecki E; Gambin Y
    Emerg Microbes Infect; 2021 Dec; 10(1):178-195. PubMed ID: 33372854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitory effects of senkyuchachosan on SARS-CoV-2 papain-like protease activity in vitro.
    Kiba Y; Tanikawa T; Hayashi T; Yokogawa T; Sano A; Suzuki R; Kitamura M
    J Nat Med; 2024 Jun; 78(3):784-791. PubMed ID: 38512650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiviral evaluation of hydroxyethylamine analogs: Inhibitors of SARS-CoV-2 main protease (3CLpro), a virtual screening and simulation approach.
    Gupta Y; Kumar S; Zak SE; Jones KA; Upadhyay C; Sharma N; Azizi SA; Kathayat RS; Poonam ; Herbert AS; Durvasula R; Dickinson BC; Dye JM; Rathi B; Kempaiah P
    Bioorg Med Chem; 2021 Oct; 47():116393. PubMed ID: 34509862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An ISG15-Based High-Throughput Screening Assay for Identification and Characterization of SARS-CoV-2 Inhibitors Targeting Papain-like Protease.
    Samrat SK; Kumar P; Liu Y; Chen K; Lee H; Li Z; Chen Y; Li H
    Viruses; 2024 Aug; 16(8):. PubMed ID: 39205213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tomatidine and Patchouli Alcohol as Inhibitors of SARS-CoV-2 Enzymes (3CLpro, PLpro and NSP15) by Molecular Docking and Molecular Dynamics Simulations.
    Zrieq R; Ahmad I; Snoussi M; Noumi E; Iriti M; Algahtani FD; Patel H; Saeed M; Tasleem M; Sulaiman S; Aouadi K; Kadri A
    Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of novel human USP2 inhibitor and its putative role in treatment of COVID-19 by inhibiting SARS-CoV-2 papain-like (PLpro) protease.
    Mirza MU; Ahmad S; Abdullah I; Froeyen M
    Comput Biol Chem; 2020 Dec; 89():107376. PubMed ID: 32979815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of potential plant-based inhibitor against viral proteases of SARS-CoV-2 through molecular docking, MM-PBSA binding energy calculations and molecular dynamics simulation.
    Gogoi B; Chowdhury P; Goswami N; Gogoi N; Naiya T; Chetia P; Mahanta S; Chetia D; Tanti B; Borah P; Handique PJ
    Mol Divers; 2021 Aug; 25(3):1963-1977. PubMed ID: 33856591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Losartan Inhibits SARS-CoV-2 Replication in Vitro.
    Nejat R; Sadr AS; Freitas B; Crabttree J; Pegan SD; Tripp RA; Najafi D
    J Pharm Pharm Sci; 2021; 24():390-399. PubMed ID: 34319871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Native Mass Spectrometry Reveals Binding Interactions of SARS-CoV-2 PLpro with Inhibitors and Cellular Targets.
    James VK; Godula RN; Perez JM; Beckham JT; Butalewicz JP; Sipe SN; Huibregtse JM; Brodbelt JS
    ACS Infect Dis; 2024 Oct; 10(10):3597-3606. PubMed ID: 39303064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-Covalent Inhibitors of SARS-CoV-2 Papain-Like Protease (PLpro): In Vitro and In Vivo Antiviral Activity.
    Velma GR; Shen Z; Holberg C; Fu J; Soleymani F; Cooper L; Ramos OL; Indukuri D; Musku SR; Rychetsky P; Slilaty S; Li Z; Ratia K; Rong L; Schenten D; Xiong R; J Thatcher GR
    J Med Chem; 2024 Aug; 67(16):13681-13702. PubMed ID: 39102360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Papain-like protease of SARS-CoV-2 inhibits RLR signaling in a deubiquitination-dependent and deubiquitination-independent manner.
    Ran XH; Zhu JW; Chen YY; Ni RZ; Mu D
    Front Immunol; 2022; 13():947272. PubMed ID: 36032116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay.
    Narayanan A; Narwal M; Majowicz SA; Varricchio C; Toner SA; Ballatore C; Brancale A; Murakami KS; Jose J
    Commun Biol; 2022 Feb; 5(1):169. PubMed ID: 35217718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel robust inhibitor of papain-like protease (PLpro) as a COVID-19 drug.
    Soleimani Asl S; Roozbahani MH
    J Biomol Struct Dyn; 2024 Aug; 42(13):6863-6870. PubMed ID: 37578047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effective inhibition of coronavirus replication by
    Xu H; Li J; Song S; Xiao Z; Chen X; Huang B; Sun M; Su G; Zhou D; Wang G; Hao R; Wang N
    Front Biosci (Landmark Ed); 2021 Oct; 26(10):789-798. PubMed ID: 34719206
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.